Vertex Pharmaceuticals Inc
Close on Nov 20, 2026Market cap $130.54BP/E 30.0Yield –
Vertex Pharmaceuticals Noncurrent operating lease liabilities by Quarter
Noncurrent operating lease liabilities ($M) ($M)
Vertex Pharmaceuticals Noncurrent operating lease liabilities: $1,978M in Q2 2026, up 29.5% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K (DB).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Noncurrent operating lease liabilities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,978 | +29.5% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,987 | +29.2% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,847 | +19.6% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,835 | +15.5% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,527 | +160.3% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,538 | +327.4% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,544 | +343.0% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,589 | +348.3% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 587 | +61.4% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2024 | Mar 31, 2024 | 360 | -3.2% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 349 | -8.1% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2023 | Sep 30, 2023 | 354 | -7.3% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 364 | -0.4% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 372 | -1.4% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 380 | +0.6% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2022 | Sep 30, 2022 | 382 | +5.2% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2022 | Jun 30, 2022 | 365 | -1.1% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 377 | +2.3% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 377 | +7.7% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 364 | – | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 369 | – | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | 369 | – | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 351 | +315.8% | Form 10-K (filed 2022-02-09) ↗ |
| Q4 2019 | Dec 31, 2019 | 84.3 | +30.1% | Form 10-K (filed 2020-02-13) ↗ |
| Q3 2019 | Sep 30, 2019 | 63 | – | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2019 | Jun 30, 2019 | 60.4 | – | Form 10-Q (filed 2019-08-01) ↗ |
| Q1 2019 | Mar 31, 2019 | 63.5 | – | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 64.8 | – | Form 10-Q (filed 2019-05-01) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Noncurrent operating lease liabilities ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/fs-lease-nc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?